Chronic graft-versus-host disease

Richard T. Maziarz; Farnoush Abar

doi:10.1007/978-1-4419-7506-5_16

Chronic graft-versus-host disease

Richard T. Maziarz, Farnoush Abar

Knight Cancer Institute

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Chronic graft-versus-host disease (cGvHD) is the single major factor influencing long-term outcome and quality of life after allogeneic transplantation. However, the presence of cGvHD has been linked to decrease in relapse rate of patients with CML, ALL, and AML. In a recent CIBMTR/NMDP analysis of ∼3500 transplant patients with cGvHD, risk of relapse was reduced by 50%. Traditionally, cGvHD has been defined as occurring after day + 100, this entity has been documented as early as 50 days to years after the transplant procedure. Chronic GvHD can emerge during or immediately following taper of immune suppressive agents or may occur as part of a continuous spectrum merging acute GvHD into cGvHD (progressive GvHD).

Original language	English (US)
Title of host publication	Blood and Marrow Transplant Handbook
Subtitle of host publication	Comprehensive Guide for Patient Care
Publisher	Springer New York
Pages	189-212
Number of pages	24
ISBN (Print)	9781441975058
DOIs	https://doi.org/10.1007/978-1-4419-7506-5_16
State	Published - 2011

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-4419-7506-5_16

Cite this

@inbook{7dfdff79a4d0454eb39a69586bc51df8,

title = "Chronic graft-versus-host disease",

abstract = "Chronic graft-versus-host disease (cGvHD) is the single major factor influencing long-term outcome and quality of life after allogeneic transplantation. However, the presence of cGvHD has been linked to decrease in relapse rate of patients with CML, ALL, and AML. In a recent CIBMTR/NMDP analysis of ∼3500 transplant patients with cGvHD, risk of relapse was reduced by 50%. Traditionally, cGvHD has been defined as occurring after day + 100, this entity has been documented as early as 50 days to years after the transplant procedure. Chronic GvHD can emerge during or immediately following taper of immune suppressive agents or may occur as part of a continuous spectrum merging acute GvHD into cGvHD (progressive GvHD).",

author = "Maziarz, {Richard T.} and Farnoush Abar",

year = "2011",

doi = "10.1007/978-1-4419-7506-5_16",

language = "English (US)",

isbn = "9781441975058",

pages = "189--212",

booktitle = "Blood and Marrow Transplant Handbook",

publisher = "Springer New York",

}

TY - CHAP

T1 - Chronic graft-versus-host disease

AU - Maziarz, Richard T.

AU - Abar, Farnoush

PY - 2011

Y1 - 2011

N2 - Chronic graft-versus-host disease (cGvHD) is the single major factor influencing long-term outcome and quality of life after allogeneic transplantation. However, the presence of cGvHD has been linked to decrease in relapse rate of patients with CML, ALL, and AML. In a recent CIBMTR/NMDP analysis of ∼3500 transplant patients with cGvHD, risk of relapse was reduced by 50%. Traditionally, cGvHD has been defined as occurring after day + 100, this entity has been documented as early as 50 days to years after the transplant procedure. Chronic GvHD can emerge during or immediately following taper of immune suppressive agents or may occur as part of a continuous spectrum merging acute GvHD into cGvHD (progressive GvHD).

AB - Chronic graft-versus-host disease (cGvHD) is the single major factor influencing long-term outcome and quality of life after allogeneic transplantation. However, the presence of cGvHD has been linked to decrease in relapse rate of patients with CML, ALL, and AML. In a recent CIBMTR/NMDP analysis of ∼3500 transplant patients with cGvHD, risk of relapse was reduced by 50%. Traditionally, cGvHD has been defined as occurring after day + 100, this entity has been documented as early as 50 days to years after the transplant procedure. Chronic GvHD can emerge during or immediately following taper of immune suppressive agents or may occur as part of a continuous spectrum merging acute GvHD into cGvHD (progressive GvHD).

UR - http://www.scopus.com/inward/record.url?scp=84892223216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892223216&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-7506-5_16

DO - 10.1007/978-1-4419-7506-5_16

M3 - Chapter

AN - SCOPUS:84892223216

SN - 9781441975058

SP - 189

EP - 212

BT - Blood and Marrow Transplant Handbook

PB - Springer New York

ER -

Chronic graft-versus-host disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this